

Healthcare from the Eye: AI-Powered Eye Exams for Early Alzheimer's Detection

Eliav Shaked

Company name: RetiSpec * Website: www.RetiSpec.ai * CEO name: Eliav Shaked *

“Beyond Neuropharma and Neurotech: Integrated Brain Control.”

Executive Summary / Investment Rational: Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. o RetiSpec is a pioneering force in AI-driven neuro-diagnostics, enabling point-of-care detection via a simple eye exam. With latest investments by industry leaders Eli Lilly and Company and Topcon Healthcare, we are advancing market entry of the world's first point-of-care Alzheimer's AI-powered detection. Deployed across >20 global sites, we address massive market needs alongside emerging disease-modifying therapeutics. • Core Technology: What is the technology, its uniqueness, and its value proposition? o Our proprietary technology integrates a hyperspectral accessory with standard FDAcleared fundus cameras, utilizing an AI predictive model intended to detect Alzheimer's pathology. This point-of-care solution is designed to deliver rapid, non-invasive screening. It has the potential to bypass the high costs, poor patient experience, and scalability bottlenecks associated with current diagnostic pathways. • Product Profile/Pipeline: Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. o Our lead asset, an AI retinal analysis software intended for Alzheimer's detection, is in late-stage development following evaluation in 14 clinical studies. We anticipate a 2027 FDA submission and a U.S. launch. Strategic partnerships with industry and global pharma leaders validate our pipeline and will help accelerate future market penetration. • Business Strategy: Briefly describe how the company will apply its core technology, generate short-term and long-term revenues. o We leverage a capital-efficient, dual-phase monetization model. Currently, our researchuse platform generates revenue by supporting global pharma trials. Post-authorization, which remains subject to regulatory review, we plan to utilize the massive global install base of fundus cameras to scale rapidly across health systems, targeting operational profitability by 2028. • What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans o Our Series A-Prime secures runway to scale recurring research-use revenue, explore broader AI-driven neuro-diagnostics, and advance global regulatory submissions for potential future authorization.